<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="202503">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00453388</url>
  </required_header>
  <id_info>
    <org_study_id>2064.00</org_study_id>
    <secondary_id>NCI-2010-00238</secondary_id>
    <secondary_id>2064.00</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT00453388</nct_id>
  </id_info>
  <brief_title>Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia</brief_title>
  <official_title>Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Fanconi Anemia Using Alternative Marrow Donors: A Phase II Dose-Finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well total-body irradiation (TBI) works when given together
      with fludarabine phosphate and cyclophosphamide followed by donor bone marrow transplant,
      mycophenolate mofetil, and cyclosporine in treating patients with Fanconi anemia (FA).
      Giving low doses of chemotherapy, such as fludarabine phosphate and cyclophosphamide, and
      TBI before or after a donor bone marrow transplant helps stop the growth of abnormal cells.
      It may also stop the patient's immune system from rejecting the donor's stem cells. The
      donated stem cells may replace the patient's immune cells and help destroy any remaining
      cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can
      also make an immune response against the body's normal cells. Giving mycophenolate mofetil
      and cyclosporine after the transplant may stop this from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Identify doses of total-body irradiation (TBI) that lead to sufficient probability of
      donor engraftment (&gt; 5% donor cluster of differentiation [CD]3 chimerism) by day +200.

      II. Evaluate the probability of severe acute graft-versus-host disease.

      SECONDARY OBJECTIVES:

      I. Evaluate the probabilities of overall survival, regimen-related toxicity (RRT), and
      recurrent hematopoietic malignancy in those patients with a prior underlying history of
      such.

      II. Examine the degree to which mixed chimerism provides for amelioration of symptoms (i.e.,
      infections due to neutropenia, hemorrhage due to thrombocytopenia) associated with bone
      marrow failure.

      III. Determine if the FA complementation group and % initial mosaicism predict engraftment
      and RRT outcomes.

      OUTLINE: Patients are assigned to 1 of 4 treatment arms.

      NOTE: Patients no longer receive pre-transplant cyclophosphamide as of February 2009.

      After completion of study treatment, patients are followed up at 6 months and then annually
      thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>February 2007</start_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Doses of TBI associated with acceptable levels of engraftment without excess GVHD</measure>
    <time_frame>By day 200</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Grades III-IV acute GVHD</measure>
    <time_frame>Up to day 100</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events assessed using adapted version of the Common Toxicity Criteria</measure>
    <time_frame>Up to 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>By day 200</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>de Novo Myelodysplastic Syndrome</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Previously Treated Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with a history of hematologic malignancy and HLA-haploidentical donor receive fludarabine phosphate (FLU) intravenously (IV) over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF orally (PO) thrice daily (TID) on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with no history of hematological malignancy and HLA-haploidentical donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with history of hematologic malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with no history of hematological malignancy and HLA-matched unrelated donors receive FLU IV over 1 hour on days -6 to -2, and undergo TBI on day -1 and allogeneic bone marrow transplant on day 0. Patients then receive CY IV over 1 hour on days 3 and 4, MMF PO TID on days 5-35, and CSP IV or PO on days 5-84, with taper until day 180, in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Bone Marrow Transplantation</intervention_name>
    <description>Undergo allogeneic bone marrow transplant</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>Allo BMT</other_name>
    <other_name>Allogeneic BMT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmun</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>9H-Purin-6-amine, 2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Oforta</other_name>
    <other_name>SH T 586</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic stem cell transplant</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>Non-myeloablative allogeneic transplant</other_name>
    <other_name>Nonmyeloablative Stem Cell Transplantation</other_name>
    <other_name>NST</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Arm I (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm II (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <arm_group_label>Arm III (2 vs 2.5 vs 3 Gy TBI dose-escalation)</arm_group_label>
    <arm_group_label>Arm IV (2 vs 2.5 vs 3 vs 1 vs 0 Gy TBI de-escalation)</arm_group_label>
    <other_name>TOTAL BODY IRRADIATION</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any patient with FA and bone marrow (BM) failure involving 2 of the following 3
             lineages: granulocyte count &lt; 0.5 x 10^9/L, platelet count &lt; 20 x 10^9/L, or
             hemoglobin &lt; 8 g/dL

          -  Any patient with FA who requires red blood cell or platelet transfusions because of
             marrow failure

          -  Any patient with FA who has a life-threatening BM failure involving a single
             hematopoietic lineage

          -  Any patient with FA and pre-existing cytogenetic abnormality including hematopoietic
             malignancy (acute myeloid leukemia [AML] or myelodysplastic syndrome [MDS]) in
             morphological remission (defined as absence of circulating blasts and bone marrow
             blasts &lt; 5% as assessed by morphology); Note that hematopoietic recovery is not
             required for remission status

          -  Patients must have a negative cytotoxic cross match with donor

          -  DONOR: Related, human leukocyte antigen (HLA)-haploidentical donors must be identical
             for one HLA haplotype and mismatched for any number of HLA-A, -B, -C, DRB1 or DQB1
             loci of the unshared haplotype

          -  DONOR: Unrelated, HLA-matched donors must be matched at HLA-A, B, C, DRB1 and DQB1 by
             deoxyribonucleic acid (DNA) typing at the highest resolution routinely available at
             the time of donor selection; a single allele mismatch at HLA-A, B, or C is allowed OR
             a single DQB1 mismatch is allowed

          -  DONOR: Bone marrow will be the only allowed hematopoietic stem cell source

          -  DONOR: Haploidentical donor selection will be based on standard institutional
             criteria, otherwise no specific prioritization will be made amongst the suitable
             available donors

        Exclusion Criteria:

          -  Patients having available HLA-matched related donors

          -  Significant organ dysfunction that would prevent compliance with conditioning,
             graft-versus-host disease (GVHD) prophylaxis, or would severely limit the probability
             of survival, such as liver disease/failure (active hepatitis, moderate to severe
             portal fibrosis/cirrhosis confirmed by biopsy or uncorrectable hepatic synthetic
             dysfunction), lung disease, or cardiac disease (ejection fraction &lt; 35%, or if unable
             to obtain ejection fraction, shortening fraction of &lt; 26%; if shortening is &lt; 26% a
             cardiology consult is required with principal investigator [PI] having final approval
             of eligibility)

          -  Human immunodeficiency virus (HIV) seropositive patients

          -  Fertile females who are unwilling to use contraceptive techniques during and for the
             twelve months following treatment, as well as females who are pregnant or actively
             breast feeding

          -  Fertile males who are unwilling to use contraceptive techniques during and for the
             twelve months following treatment

          -  AML/MDS in morphological relapse, defined as having circulating blasts or bone marrow
             blasts &gt;= 5% as assessed by morphology

          -  Active infectious disease concerns

          -  Karnofsky performance score &lt; 50 or Lansky performance score &lt; 40

          -  DONOR: Donors found to have Fanconi anemia based on chromosomal breakage analysis

          -  DONOR: Donors who are not expected to meet the minimum target dose of marrow cells (1
             x 10^8 nucleated cells/kg recipient ideal body weight [IBW]) or who are unwilling to
             be bone marrow donors

          -  DONOR: HIV-positive donors

          -  DONOR: Donors who are cross-match positive with recipient

          -  DONOR: Recipient homozygous at mismatched locus; if the recipient is homozygous at
             HLA-A, B, or C and the donor is mismatched at that locus, the donor should be
             avoided; exceptions must be discussed with the PI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Kiem</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital and Research Center at Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609-1809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University/Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 22, 2016</lastchanged_date>
  <firstreceived_date>March 27, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Fanconi Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
